About Treadwell Therapeutics, Inc.

Website
Website
Employees
Employees
11-50 employees View all
Industry
Industry
Biotechnology
Location
Location
New York,NY,US
Description
Information
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/

Treadwell Therapeutics, Inc. Alternatives

Frequently Asked Questions about Treadwell Therapeutics, Inc.

What is Treadwell Therapeutics, Inc. email format?

The widely used Treadwell Therapeutics, Inc. email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.


What is Treadwell Therapeutics, Inc. customer service number?

To contact Treadwell Therapeutics, Inc. customer service number in your country click here to find.


Who is the CEO of Treadwell Therapeutics, Inc.?

Roger Sidhu is the CEO of Treadwell Therapeutics, Inc.. Or you may call 18177247311


Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut

Search Portal

Find countless prospects outside of LinkedIn fast

Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.

Discover the source of our data

Learn more